Your session is about to expire
← Back to Search
Nasal Povidone-Iodine for Staph Infection (PAINTS Trial)
Phase 4
Waitlist Available
Led By Marin L Schweizer, PhD
Research Sponsored by Marin L. Schweizer, PhD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion (up to 3 years)
Awards & highlights
No Placebo-Only Group
Pivotal Trial
Drug Has Already Been Approved
Summary
This trial will test whether using nasal povidone-iodine at each hemodialysis session can prevent Staphylococcus aureus infections.
Who is the study for?
This trial is for adult patients who are undergoing outpatient chronic hemodialysis at one of the 16 study centers. It's not for those allergic to iodine, currently battling bacterial infections, under 18, on peritoneal or home hemodialysis, or pregnant women.
What is being tested?
The trial is testing if applying povidone-iodine ointment in the nose during each dialysis session can prevent Staphylococcus aureus infections. This stepped-wedge cluster randomized trial also assesses how feasible and acceptable this intervention is.
What are the potential side effects?
Potential side effects may include local skin reactions like redness or irritation where the povidone-iodine ointment is applied. Since it's a topical treatment, systemic side effects are less common but could include symptoms related to iodine sensitivity.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion (up to 3 years)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion (up to 3 years)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Incidence of Staphylococcus aureus bloodstream infection
Secondary study objectives
Incidence of Access related bloodstream infection by any pathogen
Incidence of Bloodstream infections by any pathogen
Incidence of Local access site infection
+3 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Nasal Povidone-Iodine Decolonization InterventionExperimental Treatment2 Interventions
Intranasal povidone-iodine (3M Skin and Nasal Antiseptic) will be applied to the patients' noses at each hemodialysis session.
Group II: Concurrent ControlActive Control1 Intervention
Standard of Care. This will be usual care at each hemodialysis center.
Find a Location
Who is running the clinical trial?
Agency for Healthcare Research and Quality (AHRQ)FED
408 Previous Clinical Trials
6,793,272 Total Patients Enrolled
Marin L. Schweizer, PhDLead Sponsor
Washington University School of MedicineOTHER
2,000 Previous Clinical Trials
2,343,960 Total Patients Enrolled
Emory HealthcareOTHER
5 Previous Clinical Trials
1,563 Total Patients Enrolled
University of PennsylvaniaOTHER
2,084 Previous Clinical Trials
42,726,746 Total Patients Enrolled
University of Illinois at ChicagoOTHER
640 Previous Clinical Trials
1,568,496 Total Patients Enrolled
3MIndustry Sponsor
159 Previous Clinical Trials
31,274 Total Patients Enrolled
Marin L Schweizer, PhDPrincipal InvestigatorUniversity of Wisconsin, Madison
1 Previous Clinical Trials
65 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You are currently receiving peritoneal dialysis or hemodialysis at home.You are pregnant.
Research Study Groups:
This trial has the following groups:- Group 1: Concurrent Control
- Group 2: Nasal Povidone-Iodine Decolonization Intervention
Awards:
This trial has 3 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.